Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hospital, Pathology Lab Cost Burden Downplayed By GAO In TC Billing Review

This article was originally published in The Gray Sheet

Executive Summary

CMS' annual recalibration of relative payment weights under PPS eventually would offset costs incurred by hospitals if labs were no longer able to bill directly to Medicare for certain pathology services, GAO finds

You may also be interested in...



Medicare lab billing

HCFA delays until Jan. 1, 2001 its requirement that independent laboratories bill hospitals, rather than HCFA, for the technical component of outpatient pathology services. Originally intended to take effect Aug. 1, the requirement forces labs to bill multiple payers for one service. Delay follows lobbying effort by the American Hospital Association, the College of American Pathologists, and the National Rural Health Association, who informed the agency in a June 29 letter that "too many adjustments are being required of hospital billing and computer systems at this time to allow them to absorb this additional change"

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

US FDA Reaffirms Commitment To Resuming Domestic Inspections As Industry Frustration Grows

Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel